202P A phase Ib/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC)
| Autor: | A. Chan, P. Dinh, D. Day, M. Slancar, V. Ganju, N.J. McCarthy, J. Lombard, D. Faltaos, M. Shilkrut, R. Wilson, C. Murphy |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | ESMO Open. 8:101391 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2023.101391 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|